Home

CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome, vaccines, and devices.

85+

$million

Invested

30+

company

Projects

7

different

Countries

9

new antibiotic classes in

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

Vedanta is fighting superbugs by boosting the body’s own microbiome.

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks
Head of Drug Resistant Infections
Wellcome Trust

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators

Boston University
RTI
CLSI
MassBio
Broad Institute
DTRA

Events

Events

08.21.18

Silver Spring, MD

FDA Development of Non-Traditional Therapies for Bacterial Infections Workshop

08.23.18

Washington, DC

Next Generation Dx Summit: Investment Plenary Panel - Changing Approaches to Sustainable Funding in Diagnostics

09.04.18

Lisbon, Portugal

ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

CARB-X News

  • 07.31.2018  |  CARB-X funds SciBac to develop a microbe drug that kills C. difficile superbugs full release

  • 07.10.2018  |  CARB-X funds Summit Therapeutics to support development of a new class of antibiotics to treat Gonorrhoea Superbug full release

  • 05.22.2018  |  UK Government and Bill & Melinda Gates Foundation join CARB-X partnership in fight against superbugs full release

See All News

In The News

  • 07.03.2018  |  MicuRx files IPO on Hong Kong exchange full story

  • 06.19.2018  |  Life sciences sector focus for UK-US event full story

  • 06.08.2018  |  An Unlikely Biotech Investor: The Government full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.